Navigation Links
Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
Date:7/1/2010

leen, bone marrow, skeleton, and lungs. The accumulation of glucocerebrosidase in the liver and spleen leads to organomegaly. Bone involvement results in skeletal abnormalities and deformities as well as bone pain crises. Deposits in the bone marrow and splenic sequestration lead to clinically significant anemia and thrombocytopenia.

Gaucher disease is the most prevalent LSD. Gaucher disease has classically been categorized into 3 clinical types. Type 1 is the most common; it is distinguished from type 2 and type 3 by the lack of neurological symptoms. Type 1 Gaucher disease is characterized by variability in signs, symptoms, severity, and progression.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the company's website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 19
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... Nov. 26, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has issued a ... (NDA) for AVP-825. AVP-825 is an investigational drug-device ... intranasally utilizing a novel Breath Powered delivery technology. ... and consistent with the preliminary feedback announced on ...
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: VIVUS ... HZNP ), Endocyte Inc. (NASDAQ: ECYT ... Theravance Inc. (NASDAQ: THRX ). Free research on ... . On Tuesday, November 25, 2014, the NASDAQ Composite ... edged 0.02% lower, to finish the day at 17,814.94, and ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... Inc. announced an agreement with the United States Department of ... prescription medication for patients with heart failure. ... plea to a single misdemeanor violation of the Food, Drug ... fine. Scios acknowledges that NATRECOR® was misbranded and ...
... Oct. 5, 2011 SV Life Sciences ("SVLS") today announced the ... joins SVLS with more than 26 years of experience in ... excited to welcome Dr. Dreismann to SVLS," said Lutz Giebel, ... and focus on investments in the diagnostics space. We believe ...
Cached Medicine Technology:SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner 2
(Date:11/28/2014)... 2014 UniWigs.com, a leader in the wig industry, ... to the next Monday. This promotion features: , ... items up to 70% off (no coupon code needed), ... Free shipping on orders over $49 , Visit http://www.uniwigs.com ... from Nov. 28th to Dec. 1st and the first 100 shoppers ...
(Date:11/28/2014)... November 28, 2014 An inventor from Flint, ... to day. "I got this idea while lying in a ... bathroom," he said. , The Bed Buddy provides a more ... to the bathroom. It eliminates the need to leave the ... comfort and dignity. Easy to use and producible in design ...
(Date:11/28/2014)... 28, 2014 talklocal ( http://www.talklocal.com ... the right service professionals by phone in about 90 seconds. ... least two tornadoes were reported to have touched down just ... was reported following the tornadoes, Denver residents now know all ... Having TalkLocal is like having local pros in over 50 ...
(Date:11/28/2014)... November 28, 2014 This report ... market along with the definite portrayal of the ... point depiction of various variables driving the development ... difficulties blocking the development of the business. ... , According to the report "Worldwide Dental ...
(Date:11/27/2014)... (PRWEB) November 28, 2014 One ... implant dentistry. The market for implant dentistry comprises ... tools/instruments. The global market for dental care is ... equipments. The dental equipment segment is composed of ... of contents at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The ...
Breaking Medicine News(10 mins):Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:TalkLocal Launches In Denver A Week After Multiple Tornadoes Hit Near City 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Dental Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3
... to be more effective than placebos in treating rapid ... study , which included 38 non-schizophrenic, non-bipolar women with ... 51 was conducted by researchers from various universities in ... shift, impulsivity and aggression when given fluvoxamine or a ...
... a national survey of more than 149,000 Americans including 23,000 ... 25% of adults with disabilities, compared to 16 per cent ... defined as having a Body Mass Index greater than 32. ... mobility difficulties and those who had not received exercise counselling ...
... on both mice and humans are showing why some people absorb ... if you eat a fatty meal or snack - a fried ... you absorb is strongly influenced by your genes. Experts know that ... fat diet is bad for you. But little has been discovered ...
... in there study are trying to observe why surgery ... ongoing. It's long been known that some older people develop ... - a condition known as Post Operative Cognitive Dysfunction (POCD).Often ... same' as they were before surgery. It was assumed, at ...
... observed that a drug already being used to treat ... male contraceptive. Researchers hypothesized N-butyldeoxynojirimycin, or NB-DNJ, which has ... work// as a male contraceptive because it affects the ... tested their theory in an animal study involving mice. ...
... the eye has prevented and stopped autoimmune eye disease in ... treatments for other// autoimmune diseases such as multiple sclerosis and ... Institute in Boston found the factor alpha-MSH can be harnessed ... prevent the onset of and stop the progression of uveitis ...
Cached Medicine News:
Hibbs Retractor with sharp teeth. Used for deep soft tissue retraction....
A general purpose instrument for use around the femur and acetabulum....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
The double action wire cutter has both side and end cutting capabilities....
Medicine Products: